These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 68Ga-PSMA PET/CT and 18F-FDG PET/CT in Renal Cell Carcinoma. Chen EJ; Tan TH; Chew MT; Chye PC Clin Nucl Med; 2020 Jul; 45(7):e317-e319. PubMed ID: 32404702 [TBL] [Abstract][Full Text] [Related]
3. Clinical utility of Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538 [TBL] [Abstract][Full Text] [Related]
4. [Malignant tumor with false negative 18F-FDG PET image]. Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients. Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403 [TBL] [Abstract][Full Text] [Related]
11. Rapidly Progressing Renal Cell Cancer of the Left Native Kidney in a Renal Transplant Recipient With Unusual Sites of Metastasis Demonstrated in Serial 18F-FDG PET/CT. Rangan B K K; Ora M; Suraj AS; Parashar A; Gambhir S Clin Nucl Med; 2019 Oct; 44(10):e574-e576. PubMed ID: 31348078 [TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT of Chromophobe Renal Cell Carcinoma With Sarcomatoid Differentiation. Lee CH; Kesari V; Legesse T; Chen W Clin Nucl Med; 2018 May; 43(5):367-369. PubMed ID: 29485439 [TBL] [Abstract][Full Text] [Related]
14. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics. Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262 [TBL] [Abstract][Full Text] [Related]
15. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936 [TBL] [Abstract][Full Text] [Related]
16. Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging. Xie F; Fu L; Zhou W Clin Nucl Med; 2022 Dec; 47(12):e758-e759. PubMed ID: 36342807 [TBL] [Abstract][Full Text] [Related]
18. Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma. Has Simsek D; Civan C; Erdem S; Sanli Y Clin Nucl Med; 2021 Jul; 46(7):579-581. PubMed ID: 33782292 [TBL] [Abstract][Full Text] [Related]
19. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817 [TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography for prostate, bladder, and renal cancer. Schöder H; Larson SM Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]